An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism [EXTENSION OF 700217760]
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2014
At a glance
- Drugs Enclomifene (Primary)
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- Sponsors Repros Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 15 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2013 Planned end date 1 Apr 2014 added as reported by ClinicalTrials.gov.